OcuCure Therapeutics Eye Drop Shows Efficacy in Primates for AMD
July 17, 2009
OcuCure Therapeutics, Inc. recently announced final results from primate testing of its lead compound OC-10X, which is currently under development as a topical eye drop treatment of age-related macular degeneration (AMD). Results indicated a 43 percent inhibition of ocular neovascularization in primate eyes treated with OC-10X.
OC-10X has demonstrated both antiangiogenic and angiolytic properties in animal models of AMD when administered as a topical eye drop. OC-10X is also being evaluated for the treatment of diabetic retinopathy.
CNV was induced (using laser photocoagulation) in both eyes of eight primates followed by intravitreal injection of OC-10X in one eye with the other eye serving as the control. Two weeks later, a second injection was administered. Four weeks after the initial laser injury, the areas of CNV lesions were measured and the difference between the smaller CNV lesion in the OC-10X treated eyes and the larger lesions in the untreated control eyes was statistically significant (p=0.025).
Long-term OC-10X safety studies were recently presented at the annual meeting of the Association for Research in Vision and Ophthalmology. These showed that after long-term topical administration of six to nine months, no changes in corneal or retinal histology or function were observed. Electroretinogram studies showed that retinal function remained normal during this long- term testing. Additionally, complete blood counts, clinical blood chemistry panels, and gross necropsy indicated no evidence of major organ dysfunction.
Read the release.
Comments
Jump down to form below to submit your own comments
2 Responses to “OcuCure Therapeutics Eye Drop Shows Efficacy in Primates for AMD”
No I don’t think you are missing anything. The company says they are developing it to be a topical treatment. This studies appears to be the first step to show that the compound works. I guess the next step will be to test it topically to see if it works and has absorption.
I believe this is just the first step.
Dominique
If I read your article and the press release correctly, the OC-10x was given as an intravitreal injection, caused regression and inhibition of CNV, and was then given topically after the initial injections?
How is this promising as a topical therapy?
I must be missing something. Look forward to hearing from you.
Randy
